Ben is Xconomy's Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
[Updated 11:02 a.m. See below.] Array BioPharma touted data less than a month ago that could shift the treatment landscape for some patients with metastatic colorectal cancer. The data... Read more »
Is one of the bigger biopharma acquisitions of the year in trouble?
This past week, antitrust regulators once again delayed Roche’s planned $4.8 billion buyout of gene therapy developer Spark Therapeutics... Read more »
It’s notoriously tough for experimental psychiatric drugs to succeed in clinical tests. BlackThorn Therapeutics wants to show that an AI-driven, precision approach can make it easier, and today it’s added another... Read more »
One of the entrants in the ultra-competitive race to develop treatments for the fatty liver disease known nonalcoholic steatohepatitis (NASH) suffered a setback in clinical testing today, but the company, Cymabay... Read more »
Cancer immunotherapy leader Merck continued to roll up oncology assets with a deal this morning to acquire privately held Tilos Therapeutics.
Drugs that rev up a patient’s immune system have changed how we treat cancers of the skin, lung, and more, offering people whose tumors have spread a chance to live longer... Read more »
The FDA today has made Zolgensma, a Novartis treatment for the rare genetic disease spinal muscular atrophy, the second approved gene therapy in the US.
The Medicines Co. and partner Alnylam Pharmaceuticals have presented new evidence supporting the long-term use of their RNA-based cholesterol lowering therapy inclisiran, which is meant to be a longer lasting alternative... Read more »
The world’s biggest annual cancer conference is just around the corner. Data presented at the American Society of Clinical Oncology meeting each year can change medical practice and make or break... Read more »
Vertex Pharmaceuticals is best known for its cystic fibrosis franchise. But over the past several years Vertex has been making inroads elsewhere, and a deal it is announcing this morning continues... Read more »
The American Academy of Neurology meeting in Philadelphia is rolling on through the end of this week. There has been plenty of news to digest already. New clinical data could herald... Read more »
[Updated 5/6/19, 9:20 am ET. See below.] A year ago, there were no FDA-approved medicines available for US patients with the debilitating rare genetic disease transthyretin amyloidosis (ATTR). Things... Read more »
This is a big moment for people diagnosed with spinal muscular atrophy, or SMA, a rare and potentially lethal genetic disorder that destroys muscles. For decades, there was no way to... Read more »
Do Wall Street investors believe that exosomes, the tiny bubbles once thought to be just cellular garbage bins, may be the key to treating a slew of potential diseases? The coming... Read more »
[Updated, 1:00 pm ET, see below.] A month after the failure of its once-promising Alzheimer’s disease drug aducanumab shattered its share price, Biogen is trying to pick up the... Read more »
Persistence and perseverance were the themes of two of our top stories this week.
First there’s the story of Nationwide Children’s Hospital. The Columbus, Ohio, hospital chose to invest in gene... Read more »
The gene therapy boom. The frustration of failure after failure in Alzheimer’s disease. The critical interplay between venture firms and “crossover” investors in a volatile, unpredictable macro-environment. The... Read more »
The gene therapy boom continued this morning with yet another acquisition.
August 27, 2019
© 2007-2019, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.